RLMD (Relmada Corp) Earnings per share growth this year
The annual earnings per share trend reported by the GURU.Markets platform concludes at 61.10, which defines the current level of this parameter. A lack of regular sales and the dependence of Relmada Therapeutics (RLMD) on external investments render cash flows unpredictable. Meanwhile, the development of neuropreparations exhibits high macro-resilience and is not subject to seasonality. The results of final clinical trials will serve as the medium-term growth driver.
Financial and market metric breakdowns for Relmada Therapeutics (RLMD)
- market value and analyst target forecast:
- business market valuation indicators:
- book capitalization information:
- debt burden and liquidity indicators:
Aggregate Debt to Capital Relmada Therapeutics|RLMD - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital relmada.com|RLMD - Company Aggregate Debts|Debts to Book Value Relmada Corp|RLMD - Company Long-Term Debt|Company Short-Term Loans and Borrowings Relmada Therapeutics|Quick Ratio relmada.com
- earnings and market multiples details:
RLMD - Company Net Income|Forward Earnings Relmada Therapeutics|RLMD - P/E Multiple|Projected Price to Earnings Ratio Relmada Corp|RLMD - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Relmada Corp|RLMD - Operating profit before deduction of amortization|Earnings per share for the last four quarters Relmada Therapeutics|RLMD - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months relmada.com|RLMD - Earnings growth in current year|Expected earnings per share growth for next year Relmada Therapeutics
- company sales and revenue statistics:
Fundamental valuation:RLMD Relmada Therapeutics Inc
Diversifying the testing protocols for NMDA receptor antagonists reduces regulatory risks for Relmada Therapeutics (RLMD). The year-over-year earnings per share (EPS) trend illustrates the effectiveness of this strategy through the lens of capital. This metric is calculated as the percentage change in EPS compared to the same period last year, reflecting the actual return of each security. The upward trajectory confirms the strengthening of the business's fundamental value. Investors should utilize this indicator to assess the company's capitalization rate.
Main competitors
Biogen Inc (BIIB) - Earnings growth in current year|NBIX (Neurocrine Biosciences Inc) - Earnings growth in current year|Earnings per share growth this year RGC (Regencell Corp)|Earnings growth in current year AXSM|Earnings growth in current year acadia-pharm.com (ACAD)|Xenon - Net earnings per share growth this year|Earnings per share increase in current year VKTX|SUPN: Net earnings per share growth this year|Catalyst Corp - Net earnings per one share growth for the current year|DNLI: Earnings growth in current year|harmonybiosciences.com - Earnings per share increase in current year|BHVN (Biohaven) - Earnings growth in current year|Earnings per share growth rate in current year Amylyx Pharmaceuticals Inc AMLX|Earnings per share growth in current year Trevi Pharma (TRVI)|PRAX (Praxis Corp) - Earnings per share increase in current year|Earnings growth in current year AVXL (Anavex Life Sciences)|Earnings growth in current year ceribell.com CBLL|PRTA - Earnings per share growth in current year|Earnings per share trend in current year ALEC|ANNX: Earnings growth in current year|Earnings per share growth rate in current year Omeros (OMER)|Net earnings per share growth this year NGNE|Earnings growth in current year acimmune.com|Net earnings per share growth this year VYGR (Voyager Therapeutics, Inc.)|Net earnings per one share growth for the current year NMRA|Earnings growth in current year SCLX (Scilex Holding Co.)|Expected net earnings per share growth this year Tevogen Bio Inc. (TVGN)|Alpha Cognition Corp - Earnings growth in current year|Cognition Therapeutics Inc. (CGTX) - Net earnings per share growth this year|Inhibikase Therapeutics, Inc. (IKT) - Earnings per share growth in current year|SAVA - Expected net earnings per share growth this year|Earnings per share growth in current year Assertio Holdings|COYA: Earnings per share increase in current year|Earnings per share growth in current year Vistagen Therapeutics (VTGN)|Earnings per share growth in current year OVID (ovidrx.com)|Earnings per share growth in current year Acumen Pharmaceuticals, Inc. ABOS|CRVO - Net earnings per share growth this year|Alterity Therapeutics Ltd - Earnings growth in current year|CLNN (Clene Inc.) - Earnings per share growth this year|pepgen.com (PEPG) - Earnings per share growth in current year|Earnings per share growth this year JUNS|ANVS (Annovis Bio) - Earnings growth in current year|Earnings per share growth rate in current year Grace Tx GRCE|Net earnings per share growth this year AIFF (Firefly Neuroscience Inc)|Earnings growth in current year anewmeds.com (KLTO)|Earnings per share growth in current year NeuroSense Therapeutics Ltd. NRSN|Earnings per share increase in current year RVPH|MTVA - Earnings per share growth in current year|Earnings per share growth rate in current year NeurAxis Inc.|heliusmedical.com (HSDT) - Earnings per share growth in current year|Passage Bio - Earnings per share increase in current year|NEUP (Neuphoria Therapeutics, Inc.) - Earnings growth in current year|Earnings per share growth rate in current year minervaneurosciences.com NERV|Earnings per share growth in current year Athira Pharma (ATHA)|Earnings per share growth in current year ADXN (Addex Therapeutics Ltd.)|Earnings per share growth in current year Alzamend Neuro ALZN|CYCN - Net earnings per share growth this year|Protagenic - Earnings growth in current year|KTTA - Earnings growth in current year|CRGT: Earnings growth in current year|Earnings per share growth this year ATXI|BCLI (Brainstorm Cell Therapeutics, Inc.) - Earnings growth in current year|Earnings growth in current year Cara Therapeutics Inc|Net earnings per share growth this year CHRO (Chromocell Therapeutics)|ELYM (eliemtx.com) - Earnings per share increase in current year|Intra-Cellular Therapies, Inc. - Net earnings per share growth this year|Net earnings per one share growth for the current year LBPH (Longboard Pharmaceuticals Inc)|Marinus - Earnings growth in current year|Earnings per share increase in current year NKGN (NKGen Biotech Corp)|NRBO: Earnings growth in current year|Earnings per share growth rate in current year sagerx.com (SAGE)|Earnings per share growth in current year Synaptogenix|TRVN: Earnings per share increase in current year|Earnings growth in current year VIGL|Earnings growth in current year anewmeds.com (WENA)|Earnings per share growth in current year Cerevel Therapeutics CERE
